The new name for Medical Solutions is officially Source BioScience - a really catchy name!
Read the last postings under [MLS] and you'll see it was way-back in 2007.

Oh dear, Zzzz.

Er, anyone still there?
. . . . . This new Business is slightly different, having bought another company recently - but then failing companies always think they can "trade" out of problems. . . . .
The problem?

For me it's the regular holding of investor-meetings in Nottingham ( M1- half-way, turn right...keep your speed down; this county uses cameras for pension funding.).

Anyone living near Nottingham - and going to the AGM - can you tell us how things are.....did they show any product?
//
No? - well, no change then.

Source BioScience plc

("Source BioScience" or the "Company")

NHS publishes Implementation Guidelines for Source BioScience's Automated
Cervical Cancer Screening Technology

Cervical Screening Wales are first in the UK to adopt the new technology

Source BioScience (LSE: SBS), the international diagnostics and genetic
analysis business, is pleased to announce that the National Health Service
Cancer Screening Programmes (`NHSCSP') has published its guidelines for the use
of the BD FocalPoint technology for cervical cancer screening in the UK.

Following the publication of the guidelines, Cervical Screening Wales (`CSW')
announced their commitment to implement the technology across Wales from 1
January 2012, the first screening service in the UK to introduce automated
imaging into the cervical cancer screening programme. The agreement to provide
the BD FocalPoint to CSW is worth up to GBP0.6 million to July 2015.

The BD FocalPoint is the only automated technology for cervical cancer
screening approved for use by the NHS and is able to analyse and identify up to
25% of screening samples that can be reported as "all clear", requiring no
manual examination. With over 3.6 million tests being undertaken across England
and Wales during 2009/10, this represents a significant reduction in laboratory
workload and the need for additional staffing and outsourcing. It will also
help laboratories achieve the mandatory 14 day screening deadline for patients
to receive their test results promised to patients under the Department of
Health's Cancer Reform Strategy.

Dr Nick Ash, CEO at Source BioScience, commented: "The publication of the
implementation guidelines enables us to facilitate the introduction of
automated imaging to the NHS standards across England and Wales. There has been
considerable interest in adopting the technology from a large number of NHS
Trusts looking to improve screening turnaround times even further and we're
delighted to announce that Cervical Screening Wales are the first screening
service to adopt the technology in the UK."

He added: "Source BioScience is now able to provide customers with a unique and
complete solution for cervical cancer screening from sample collection,
processing, imaging and diagnostic testing, including HPV testing."

Bryan Rose, Head of Programme for Cervical Screening Wales said: "We are
pleased to be the first service to formally adopt the BD FocalPoint system for
the application of "No Further Review" (`NFR') in the cervical screening
programme in Wales. CSW has run an independent assessment of the technology
which has led us to recognise for some time the benefits of using automated
imaging for cervical screening. Following recognition in the MAVERIC study of
its utility and the recent publication by the NHSCSP of specific guidelines for
the use of BD FocalPoint technology, which establishes best practice, we can
now confidently implement the technology into our screening programme. The
technology will assist our laboratories to improve turnaround times within our
defined standards and enhance the quality of service that we provide for women
in Wales."

Hilja Ibert, VP GM BD Diagnostic Systems Europe commented: "The implementation
of BD FocalPoint is a direct outcome of our focus on improving health outcomes
for patients by providing laboratories with solutions that improve quality,
inform medical decisions and enhance laboratory system productivity. We
continuously invest in developing innovative solutions and technologies that
will further support and enhance the cervical cancer screening programs. We are
proud of our long-standing partnership with Source BioScience in the UK, for
their expert support and distribution of these technologies and the rapid
implementation of BD FocalPoint NFR."

--ENDS--

RSI on viagra.

Another strong candle.

Interim Management Statement.

Half Yearly report

Financial highlights

* Revenue increased by 11% to £8.4 million (2011: £7.6 million)

* EBITDA of £1.3 million (2011: £0.5 million)

* Operating profit of £0.5 million (2011: loss of £0.2 million)

* Profit before tax of £0.4 million (2011: loss of £0.2 million)

* EPS of 0.20p basic (2011: loss of 0.09p basic)

* Cash balance of £1.8 million (31 December 2011: £1.1 million)

Operational highlights

* Developments in LifeSciences business delivering growth:

*
+ DNA sequencing has grown by 60% year on year, driven by our Overnight
Service

+ Phase III of GenomeCube®, our proprietary web-based search engine and
bioinformatics tool is underway; this is enabling globalisation of
product portfolio and the appointment of overseas franchise
distributors

I'm in as of this morning..good story developing here (imho)

A load of BUYS today and only 3 SELLS out of 37 trades




Trades

Show the last 25 50 100 250 500 1000 All trades - Showing all 37 trades since market opening.

Latest trades

Time Price Volume Value Bid Ask B/S
15:17:55 12p 82,811 £9,937 11.75p 12p Buy
15:07:18 11.9p 3,250 £387 11.75p 12p Buy
14:33:04 11.9p 21,299 £2,535 11.75p 12p Buy
14:20:37 11.9p 12,437 £1,480 11.75p 12p Buy
14:08:54 11.9p 15,000 £1,785 11.75p 12p Buy
13:44:24 11.9p 5,000 £595 11.75p 12p Buy
13:26:40 11.9p 840 £100 11.75p 12p Buy
12:44:26 11.9p 10,084 £1,200 11.75p 12p Buy
12:38:43 11.9p 4,000 £476 11.75p 12p Buy
12:25:14 11.9p 18,520 £2,204 11.75p 12p Buy
12:11:27 11.9p 8,286 £986 11.75p 12p Buy
11:57:29 11.9p 8,403 £1,000 11.75p 12p Buy
11:47:33 11.9p 25,000 £2,975 11.75p 12p Buy
11:45:35 11.8p 4,662 £550 11.75p 12p Sell
11:19:12 11.9p 750 £89 11.75p 12p Buy
11:16:16 11.9p 3,500 £416 11.75p 12p Buy
11:12:39 11.9p 3,000 £357 11.75p 12p Buy
11:08:47 11.92p 10,000 £1,192 11.75p 12p Buy
11:05:13 11.9p 15,000 £1,785 11.75p 12p Buy
11:04:12 11.9p 16,893 £2,010 11.75p 12p Buy
11:01:05 11.91p 5,000 £596 11.75p 12p Buy
11:00:19 11.91p 25,314 £3,015 11.75p 12p Buy
10:52:21 11.91p 15,153 £1,805 11.75p 12p Buy
10:49:54 11.91p 23,280 £2,773 11.75p 12p Buy
10:42:06 11.92p 20,000 £2,384 11.75p 12p Buy
10:28:01 11.97p 5,112 £612 11.75p 12p Buy
10:25:53 11.88p 25,000 £2,970 11.75p 12p Buy
9:57:11 11.91p 329 £39 11.75p 12p Buy
9:55:35 11.65p 95,587 £11,136 11.75p 12p Sell
9:09:16 11.87p 92,117 £10,934 11.5p 12p Buy
9:02:47 11.71p 2,022 £237 11.5p 12p Sell
9:00:14 11.92p 8,243 £983 11.5p 12p Buy
8:26:41 11.92p 2,000 £238 11.5p 12p Buy
8:12:48 11.92p 4,048 £483 11.5p 12p Buy
8:04:03 11.87p 8,424 £1,000 11.5p 12p Buy
8:01:12 11.87p 8,000 £950 11.5p 12p Buy
8:01:06 11.87p 3,118 £370 11.5p 12p Buy


Today's summary Bid 11.75p
Ask 12p
High 12p
Low 11.65p
Open 11.75p
Previous close 11.75p
Mid price 11.88p
Change +0.25p (2.128%)
Volume 611.5K



2 of those buys were mine at 11.91p ....onwards and upwards...not expecting a quick return so will be an LTH....liking the story!

topped up today

Final Results

Financial highlights

* Revenue increased by 8% to GBP16.4 million (2011: GBP15.2 million)

* Operating profit more than doubled to GBP1.2 million (2011: GBP0.5 million
adjusted*)

* Profit before tax of GBP1.0 million (2011: GBP0.4 million adjusted*)

* EBITDA increased by 43% to GBP2.7 million (2011: GBP1.9 million adjusted*)

* Profit after tax of GBP3.5 million (2011: loss of GBP2.8 million)

* EPS 1.70 pence (2011: loss per share 1.37 pence)

* Cash generated from operating activities of GBP3.3 million (2011: GBP0.6
million)

* Cash balance of GBP2.2 million (2011: GBP1.1 million) and net debt of GBP0.9
million (2011: GBP2.3 million)

Offer Update

SOURCE BIOSCIENCE PLC ("SOURCE BIOSCIENCE" OR THE "COMPANY")
RECOMMENDED CASH OFFER FOR VINDON HEALTHCARE PLC ("VINDON")

OFFER DECLARED UNCONDITIONAL IN ALL RESPECTS



Source BioScience plc (LSE: SBS) the international diagnostics and genetic analysis services business, announces that its circa GBP 12.2 million recommended cash offer for Vindon Healthcare plc is now declared unconditional in all respects.

Highlights

· On 13 September 2013, Source BioScience announced that it had received valid acceptances in respect of more than 90 per cent. of the entire issued share capital of Vindon and the Offer had become unconditional as to acceptances
· The acquisition is part funded by the Firm Placing which raised GBP 9.5 million (gross) from existing and new institutional investors and a new banking facility
· Following the admission to trading of the Firm Placing Shares at 8.00 a.m. on 13 September 2013 and the conclusion of other completion matters, the Offer is now unconditional in all respects
· The Offer will remain open for acceptances until further notice. At least 14 days' notice will be given before Source BioScience closes the Offer to further acceptances. In accordance with the Companies Act, compulsory acquisition measures may be used to acquire Vindon Shares not assented to the Offer
· Vindon Shareholders who have not yet accepted the Offer are reminded to do so as soon as possible. Details of the procedure for doing so are set forth in the Offer Document (including, in the case of certificated Vindon Shares, the Form of Acceptance) sent to Vindon Shareholders on 7 August 2013
· The residual net proceeds of the Firm Placing (after partial funding of the consideration for the Offer and related expenses) will be used, together with the circa GBP 0.8 net proceeds of the recently completed million Open Offer, to fund additional organic and selected acquisitive growth initiatives for the enlarged Source BioScience Group

The Offer will remain open for acceptances until further notice. At least 14 days' notice will be given before Source BioScience closes the Offer to further acceptances. Vindon Shareholders who have not yet accepted the Offer are reminded to do so as soon as possible. Details of the procedure for doing so are set forth in the Offer Document (including, in the case of certificated Vindon Shares, the Form of Acceptance) sent to Vindon Shareholders on 7 August 2013.

Source Bioscience - was Medical Solutions....DYOR.
This has been a sorry-state investment . . . so at last the fools (like me!), that believed Execs words have their hopes finalised.
Well, apart from anyone that bought recently, this has been dire - and the Sept 2016 OFFER at least provides a decent EXIT.....at a paper loss....but then, the money was lost to any better "Good Use" from early days - as they tried to maintain interest, etc.


The lack of Posts since Sept. 2013 indicates how little excitement there has been in this dire business.